G6PD activator AG1

CAS No. 421581-52-4

G6PD activator AG1( —— )

Catalog No. M29654 CAS No. 421581-52-4

G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 μΜ.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 689 In Stock
25MG 1378 In Stock
50MG 1788 In Stock
100MG 2256 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock

Biological Information

  • Product Name
    G6PD activator AG1
  • Note
    Research use only, not for human use.
  • Brief Description
    G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 μΜ.
  • Description
    G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 μΜ. G6PD activator AG1 reduces hemolysis of human erythrocytes.AG1 (50, 100, 250, 500, 750, 1000 nM) of 1μM increases the viability by 20% and the proteolytic stability of Canton G6PD in SH-SY5Y cells. AG1 has no effect when G6PD was knocked down by siRNA, supporting the specificity of AG1 toward G6PD.AG1 (1-5 μΜ; pre-incubated overnight) reduces the extent of hemolysis with 5 μΜ in human erythrocytes suspension (5%) exposed to either 1 mM chloroquine (CQ; 4 hours) or diamide (a GSH oxidant; 4 hours). AG1 increases GSH levels and reduced ROS levels together with increased G6PD activity under these drug-induced oxidative stress.AG1 has no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6-phosphogluconate dehydrogenase (6PGD), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), aldehyde dehydrogenase 2 (ALDH2), and aldehyde dehydrogenase 3A1 (ALDH3A1).
  • In Vitro
    AG1 (50, 100, 250, 500, 750, 1000 nM) of 1μM increases the viability by 20% and the proteolytic stability of Canton G6PD in SH-SY5Y cells. AG1 has no effect when G6PD was knocked down by siRNA, supporting the specificity of AG1 toward G6PD. AG1 (1-5 μΜ; pre-incubated overnight) reduces the extent of hemolysis with 5 μΜ in human erythrocytes suspension (5%) exposed to either 1 mM chloroquine (CQ; 4 hours) or diamide (a GSH oxidant; 4 hours). AG1 increases GSH levels and reduced ROS levels together with increased G6PD activity under these drug-induced oxidative stress. AG1 has no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6-phosphogluconate dehydrogenase (6PGD), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), aldehyde dehydrogenase 2 (ALDH2), and aldehyde dehydrogenase 3A1 (ALDH3A1).
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    IC50: 3 μΜ (G6PD)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    421581-52-4
  • Formula Weight
    438.65
  • Molecular Formula
    C24H30N4S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 20.83 mg/mL (47.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
  • SMILES
    C1(CCNCCSSCCNCCC2=CNC3=C2C=CC=C3)=CNC4=C1C=CC=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kaitlyn Ryan, et al. Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency. Pharmacol Ther. 2020 Dec 14;222:107788.
molnova catalog
related products
  • Acevaltrate

    Acevaltrate displays high cytotoxicity against GLC(4), a human small-cell lung cancer cell line, and against COLO 320, a human colorectal cancer cell line, with IC50 values of 1-6 uM.

  • L-Aspartic acid pota...

    L-aspartic acid potasium salt(VX-548) is an amino acid widely found in plants and animals.L-aspartic acid potasium salt drives the production of nitrogen oxides, which promotes phagocytosis and contributes to fish survival.

  • TM-N1324

    TM-N1324 is a GPR39 agonist. TM-N1324 activates human GPR39 with high efficacy and potencies of 280 nM and 9 nM in the absence and presence of Zn2+, respectively.